Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intravenous (IV) Abatacept Clear all

Conditions: Rheumatoid Arthritis (RA)
Interventions: Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 70
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 63 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 114
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more

Conditions: Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
Interventions: Belatacept, VIB4920, Thymoglobulin, Methylprednisolone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 19
States / cities: Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more

Conditions: Organ Transplantation
Interventions: Belatacept, Sirolimus, Alemtuzumab; Drug
Lead sponsor: Allan D Kirk, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 39 more

Conditions: Juvenile Rheumatoid Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 10
States / cities: Omaha, Nebraska • Livingston, New Jersey • New Hyde Park, New York + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, placebo, methotrexate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 19
States / cities: Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more

Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy; Drug · Procedure · Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 66 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more

Conditions: Crohn's Disease
Interventions: abatacept, placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more

Conditions: Transplantation
Interventions: belatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions: Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 12
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more

Conditions: Sjogren's Syndrome
Interventions: Orencia, Placebo; Biological · Other
Lead sponsor: Arthritis & Rheumatism Associates, P.C.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: belatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Austin, Texas • Dallas, Texas

Conditions: Transplant Rejection
Interventions: Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Belatacept; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Kidney Transplantation
Interventions: Belatacept; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Psoriatic Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 19
States / cities: Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more

Conditions: Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis
Interventions: Group 1 or Orencia treated group, Group 2 (DMARDS treated group); Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis
Interventions: Abatacept (BMS-188667), Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more

Conditions: End Stage Renal Disease, Antibody Mediated Rejection
Interventions: Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, DMARDs; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Renal Transplantation
Interventions: Alemtuzumab, rabbit antithymocyte globulin, Belatacept, Tacrolimus, Mycophenolate mofetil, early cessation of steroids; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more

Search by objective public record fields.

Methotrexate-Inadequate Response Study

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

Belatacept Post Depletional Repopulation to Facilitate Tolerance

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

A Study of Abatacept in Patients With Active Crohn's Disease

Subcutaneous Pharmacokinetics of Belatacept

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Sjogrens Syndrome Measured by Ultrasound

LEA29Y (Belatacept) Emory Edmonton Protocol

A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

Bela 8 Week Dosing

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis

Abatacept With Methotrexate- Phase IIB

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

Rheumatoid Arthritis Memory B Cells and Abatacept

Belatacept Early Steroid Withdrawal Trial